Homologous recombination deficiency (HRD) status
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-HRD-STATUS |
|---|---|
| Type | Biomarker |
| Aliases | BRCAnessHR-deficientHRD statusСтатус дефіциту гомологічної рекомбінації |
| Status | reviewed 2026-04-26 |
| Diseases | None declared |
| Sources | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Biomarker Facts
| Biomarker type | gene_mutation |
|---|---|
| Measurement | MethodComposite: BRCA1/2 (germline + somatic) + genomic instability score (Myriad myChoice CDx, FoundationOne CDx HRD) Unitscategorical: HRD-positive (BRCA1/2-mutant OR GIS ≥42) | HRD-negative |
| Related biomarkers | BIO-BRCA1-BRCA2-GERMLINE |
Used By
Actionability
BMA-HRD-STATUS-BREAST- Germline BRCA1/2 mutation (gBRCAm) breast cancer (HER2-negative, ~5-10% of metastatic): o...BMA-HRD-STATUS-OVARIAN- HRD-positive high-grade serous ovarian carcinoma (~50% — encompassing BRCA1/2-mutated and...BMA-HRD-STATUS-PDAC- Germline BRCA1/2 mutation in metastatic PDAC (~5-7%): olaparib monotherapy maintenance af...BMA-HRD-STATUS-PROSTATE- Homologous-recombination-repair (HRR) gene alterations in metastatic castration-resistant...
Biomarker
BIO-HRD-ASSAY-DISTINCTION- HRD assay distinction (Myriad myChoice CDx vs FoundationOne CDx)
Diseases
DIS-OVARIAN- Ovarian carcinoma (high-grade serous predominant)
Indications
IND-OVARIAN-ADVANCED-1L-CARBO-PACLI-HRD-NEG- IND-OVARIAN-ADVANCED-1L-CARBO-PACLI-HRD-NEGIND-OVARIAN-ADVANCED-1L-CARBO-PACLI-HRD-OLAP- IND-OVARIAN-ADVANCED-1L-CARBO-PACLI-HRD-OLAPIND-OVARIAN-MAINT-PARPI-HRD-NIRAPARIB- IND-OVARIAN-MAINT-PARPI-HRD-NIRAPARIBIND-OVARIAN-MAINTENANCE-OLAPARIB- IND-OVARIAN-MAINTENANCE-OLAPARIB
Questionnaires
QUEST-OVARIAN-1L-STUB- Ovarian carcinoma — first line